Compare GOTU & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOTU | AUTL |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.2M | 596.2M |
| IPO Year | 2019 | 2025 |
| Metric | GOTU | AUTL |
|---|---|---|
| Price | $2.56 | $1.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $3.75 | ★ $8.73 |
| AVG Volume (30 Days) | 475.6K | ★ 1.4M |
| Earning Date | 08-27-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $15.28 | $98.68 |
| Revenue Next Year | $13.22 | $28.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $1.40 | $1.18 |
| 52 Week High | $3.35 | $2.58 |
| Indicator | GOTU | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 75.07 | 43.44 |
| Support Level | $2.24 | $1.84 |
| Resistance Level | $2.65 | $1.92 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 79.59 | 34.48 |
Gaotu Techedu Inc is a technology-driven education company in China that enables lifelong learning through AI-powered solutions that cultivate interest and drive continuous growth. The Company provides AI-powered, product-led learning solutions for learners from pre-school to adulthood. By combining rare, high-caliber teaching resources with AI-enhanced tools and content, Gaotu creates engaging and effective learning experiences delivered through both online and offline channels. AI and data analytics permeate the Company's operations, adapting content and teaching methods to individual learner needs, improving efficiency, and driving sustained learning progress.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.